Data | Hora | Fonte | Título | Código | Companhia |
07/04/2017 | 16:23 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
27/02/2017 | 17:09 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
27/02/2017 | 12:30 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(b) (15-12b) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
21/02/2017 | 13:19 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
16/02/2017 | 19:54 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
16/02/2017 | 19:14 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
16/02/2017 | 17:19 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
16/02/2017 | 12:42 | Edgar (US Regulatory) | Amended Statement of Ownership: Solicitation (sc 14d9/a) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
16/02/2017 | 12:15 | Edgar (US Regulatory) | Amended Tender Offer Statement by Third Party (sc To-t/a) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
16/02/2017 | 11:52 | Edgar (US Regulatory) | (25-NSE) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
14/02/2017 | 13:48 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
13/02/2017 | 19:16 | Edgar (US Regulatory) | Amended Quarterly Report (10-q/a) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
09/02/2017 | 12:53 | Edgar (US Regulatory) | Schedule 13g | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
06/02/2017 | 10:35 | Business Wire | ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
19/01/2017 | 20:19 | Edgar (US Regulatory) | Statement of Ownership: Solicitation (sc 14d9) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
19/01/2017 | 20:07 | Edgar (US Regulatory) | Tender Offer Statement by Third Party (sc To-t) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
18/01/2017 | 20:22 | Edgar (US Regulatory) | Statement of Beneficial Ownership (sc 13d) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
18/01/2017 | 13:48 | PR Newswire (US) | Ariad Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of ARIA Shareholders | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
11/01/2017 | 20:24 | Edgar (US Regulatory) | Written Communication Relating to an Issuer or Third Party (sc To-c) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
09/01/2017 | 20:05 | PR Newswire (US) | Harwood Feffer LLP Announces Investigation of ARIAD Pharmaceuticals, Inc. | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
09/01/2017 | 19:38 | Edgar (US Regulatory) | Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
09/01/2017 | 15:46 | Business Wire | ARIAD PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
09/01/2017 | 11:02 | Business Wire | ARIAD Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
09/01/2017 | 11:00 | Business Wire | Takeda to Acquire ARIAD Pharmaceuticals, Inc. | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
03/01/2017 | 10:35 | Business Wire | ARIAD to Present at the 35th Annual J.P. Morgan Healthcare Conference | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
13/12/2016 | 12:25 | InvestorsHub NewsWire | Traders News Issues New Reports and Features a New OTCQB Company Profile | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
07/12/2016 | 10:35 | Business Wire | ARIAD’s Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival in ALTA Study | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
06/12/2016 | 10:35 | Business Wire | ARIAD Announces Data Presentations at American Society of Hematology Meeting | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
05/12/2016 | 10:35 | Business Wire | ARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Pat... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
02/12/2016 | 19:05 | Business Wire | ARIAD to Host Webcast and Conference Call on Brigatinib Data Presentations at the World Conference on Lung Cancer | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |